DK2621481T4 - Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser - Google Patents
Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser Download PDFInfo
- Publication number
- DK2621481T4 DK2621481T4 DK11764655.4T DK11764655T DK2621481T4 DK 2621481 T4 DK2621481 T4 DK 2621481T4 DK 11764655 T DK11764655 T DK 11764655T DK 2621481 T4 DK2621481 T4 DK 2621481T4
- Authority
- DK
- Denmark
- Prior art keywords
- castration
- vegf
- met
- treatment
- prostate cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38695910P | 2010-09-27 | 2010-09-27 | |
US201161481671P | 2011-05-02 | 2011-05-02 | |
PCT/US2011/053233 WO2012044572A1 (en) | 2010-09-27 | 2011-09-26 | Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
Publications (2)
Publication Number | Publication Date |
---|---|
DK2621481T3 DK2621481T3 (da) | 2019-10-21 |
DK2621481T4 true DK2621481T4 (da) | 2023-01-09 |
Family
ID=44741730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11764655.4T DK2621481T4 (da) | 2010-09-27 | 2011-09-26 | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
Country Status (22)
Country | Link |
---|---|
US (4) | US20140057943A1 (da) |
EP (1) | EP2621481B2 (da) |
JP (2) | JP6158705B2 (da) |
KR (1) | KR101882328B1 (da) |
CN (1) | CN103402505A (da) |
AR (1) | AR085195A1 (da) |
AU (2) | AU2011307304C1 (da) |
BR (1) | BR112013007220A2 (da) |
CA (1) | CA2812750C (da) |
DK (1) | DK2621481T4 (da) |
EA (1) | EA027476B1 (da) |
ES (1) | ES2754973T5 (da) |
FI (1) | FI2621481T4 (da) |
HU (1) | HUE045810T2 (da) |
IL (1) | IL225507B (da) |
MX (1) | MX352926B (da) |
PL (1) | PL2621481T5 (da) |
PT (1) | PT2621481T (da) |
SI (1) | SI2621481T2 (da) |
TW (2) | TW201738213A (da) |
UA (1) | UA114172C2 (da) |
WO (1) | WO2012044572A1 (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106420743A (zh) | 2010-07-16 | 2017-02-22 | 埃克塞里艾克西斯公司 | C‑met调节剂药物组合物 |
WO2012044572A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
BR112013020362A2 (pt) | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
KR20140025496A (ko) * | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
BR112014006702A2 (pt) * | 2011-09-22 | 2017-06-13 | Exelixis Inc | método para tratar osteoporose |
CA2852771C (en) | 2011-10-20 | 2019-11-26 | Exelixis, Inc. | Process for preparing quinoline derivatives |
TW201818937A (zh) * | 2011-11-08 | 2018-06-01 | 美商艾克塞里克斯公司 | 治療癌症之方法 |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
CN103664776B (zh) * | 2012-09-26 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
MX366003B (es) | 2013-03-15 | 2019-06-24 | Exelixis Inc | Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida. |
KR20150138268A (ko) * | 2013-04-04 | 2015-12-09 | 엑셀리시스, 인코포레이티드 | 암을 치료하기 위한 약물 병용요법 |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
MX2021001583A (es) | 2014-02-14 | 2023-02-08 | Exelixis Inc | Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso. |
US10159666B2 (en) | 2014-03-17 | 2018-12-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
CN106715397B (zh) | 2014-07-31 | 2021-07-23 | 埃克塞里艾克西斯公司 | 制备氟-18标记的卡博替尼及其类似物的方法 |
EP3177311A1 (en) | 2014-08-05 | 2017-06-14 | Exelixis, Inc. | Drug combinations to treat multiple myeloma |
EP3219205A1 (en) * | 2016-03-18 | 2017-09-20 | Nihon Medi-Physics Co., Ltd. | Method for producing a non human animal model of osteoblastic bone metastasis |
EP3442531A1 (en) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
CN108503650B (zh) * | 2017-02-27 | 2021-02-12 | 北京赛特明强医药科技有限公司 | 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用 |
WO2019154133A1 (zh) * | 2018-02-11 | 2019-08-15 | 北京赛特明强医药科技有限公司 | 二噁烷并喹啉类化合物及其制备方法与应用 |
MA48776A (fr) | 2017-05-26 | 2020-04-08 | Exelixis Inc | Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation |
AU2018395222B2 (en) | 2017-12-27 | 2023-06-08 | Coa Therapeutics, Inc. | Small molecule modulators of pantothenate kinases |
AU2018397486A1 (en) | 2017-12-27 | 2020-08-13 | Coa Therapeutics, Inc. | Methods of treating disorders associated with castor |
CR20230287A (es) | 2018-01-26 | 2023-07-26 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358) |
EP4262814A1 (en) * | 2020-12-16 | 2023-10-25 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
WO2003033472A1 (fr) | 2001-10-17 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes |
GB0219746D0 (en) | 2002-08-23 | 2002-10-02 | Inst Of Ex Botany Ascr | Azapurine derivatives |
WO2004035572A1 (ja) | 2002-10-21 | 2004-04-29 | Kirin Beer Kabushiki Kaisha | N−{2−クロロ−4−[(6,7−ジメトキシ−4−キノリル)オキシ]フェニル}−n’−(5−メチル−3−イソキサゾリル)ウレアの塩の結晶形 |
AU2003280599A1 (en) | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
KR101089462B1 (ko) | 2002-11-04 | 2011-12-07 | 아스트라제네카 아베 | Src 티로신 키나제 억제제로서의 퀴나졸린 유도체 |
MXPA05006123A (es) | 2002-12-13 | 2005-09-30 | Neurogen Corp | Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina. |
MXPA05006335A (es) | 2002-12-18 | 2005-08-26 | Pfizer Prod Inc | Derivados biciclicos para el tratamiento del crecimiento celular anormal. |
EP1575591A4 (en) | 2002-12-23 | 2007-09-12 | Ariad Pharma Inc | HETEROCYCLES AND ITS USE |
AU2003292838A1 (en) | 2002-12-27 | 2004-07-29 | Kirin Beer Kabushiki Kaisha | Therapeutic agent for wet age-related macular degeneration |
DK2392564T3 (da) † | 2003-09-26 | 2014-01-13 | Exelixis Inc | c-Met-modulatorer og anvendelsesfremgangsmåder |
WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
US20080004273A1 (en) | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
PL2183254T3 (pl) * | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitory aktywności białkowej kinazy tyrozynowej |
TW200922590A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
WO2009140549A1 (en) * | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
CA2738583A1 (en) | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
KR20110084455A (ko) | 2008-11-13 | 2011-07-22 | 엑셀리시스, 인코포레이티드 | 퀴놀린 유도체를 제조하는 방법 |
JP2010126530A (ja) * | 2008-12-01 | 2010-06-10 | Takeda Chem Ind Ltd | 縮合複素環誘導体およびその用途 |
WO2010065838A1 (en) | 2008-12-04 | 2010-06-10 | Exelixis, Inc. | Methods of preparing quinoline derivatives |
SG173014A1 (en) * | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
CA2768370A1 (en) | 2009-07-17 | 2011-01-20 | Exelixis, Inc. | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
WO2011031840A1 (en) | 2009-09-09 | 2011-03-17 | Quintiles Transnational Corp. | Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders |
MX2012010506A (es) | 2010-03-12 | 2012-10-15 | Exelixis Inc | Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida. |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
CN106420743A (zh) | 2010-07-16 | 2017-02-22 | 埃克塞里艾克西斯公司 | C‑met调节剂药物组合物 |
EP2593091A1 (en) | 2010-07-16 | 2013-05-22 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
AU2011307306A1 (en) | 2010-09-27 | 2013-05-02 | Exelixis, Inc. | Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
EP2621483A1 (en) | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
WO2012044572A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
EP2643001A4 (en) | 2010-11-22 | 2014-02-19 | Glaxosmithkline Ip Dev Ltd | METHOD OF TREATING CANCER |
BR112013020362A2 (pt) | 2011-02-10 | 2018-05-29 | Exelixis Inc | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
KR20140025496A (ko) | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
BR112014006702A2 (pt) | 2011-09-22 | 2017-06-13 | Exelixis Inc | método para tratar osteoporose |
CA2852771C (en) | 2011-10-20 | 2019-11-26 | Exelixis, Inc. | Process for preparing quinoline derivatives |
TW201818937A (zh) | 2011-11-08 | 2018-06-01 | 美商艾克塞里克斯公司 | 治療癌症之方法 |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
CN114129566A (zh) | 2012-09-07 | 2022-03-04 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
MX366003B (es) | 2013-03-15 | 2019-06-24 | Exelixis Inc | Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida. |
KR20150138268A (ko) | 2013-04-04 | 2015-12-09 | 엑셀리시스, 인코포레이티드 | 암을 치료하기 위한 약물 병용요법 |
-
2011
- 2011-09-26 WO PCT/US2011/053233 patent/WO2012044572A1/en active Application Filing
- 2011-09-26 DK DK11764655.4T patent/DK2621481T4/da active
- 2011-09-26 UA UAA201305315A patent/UA114172C2/uk unknown
- 2011-09-26 KR KR1020137010372A patent/KR101882328B1/ko active IP Right Grant
- 2011-09-26 MX MX2013003594A patent/MX352926B/es active IP Right Grant
- 2011-09-26 AU AU2011307304A patent/AU2011307304C1/en active Active
- 2011-09-26 FI FIEP11764655.4T patent/FI2621481T4/fi active
- 2011-09-26 HU HUE11764655A patent/HUE045810T2/hu unknown
- 2011-09-26 EA EA201390465A patent/EA027476B1/ru not_active IP Right Cessation
- 2011-09-26 US US13/876,290 patent/US20140057943A1/en not_active Abandoned
- 2011-09-26 JP JP2013530386A patent/JP6158705B2/ja active Active
- 2011-09-26 CN CN2011800565800A patent/CN103402505A/zh active Pending
- 2011-09-26 EP EP11764655.4A patent/EP2621481B2/en active Active
- 2011-09-26 PL PL11764655.4T patent/PL2621481T5/pl unknown
- 2011-09-26 CA CA2812750A patent/CA2812750C/en active Active
- 2011-09-26 ES ES11764655T patent/ES2754973T5/es active Active
- 2011-09-26 SI SI201131802T patent/SI2621481T2/sl unknown
- 2011-09-26 PT PT117646554T patent/PT2621481T/pt unknown
- 2011-09-27 AR ARP110103539A patent/AR085195A1/es unknown
- 2011-09-27 TW TW106105784A patent/TW201738213A/zh unknown
- 2011-09-27 TW TW100134883A patent/TW201302709A/zh unknown
- 2011-11-26 BR BR112013007220A patent/BR112013007220A2/pt not_active IP Right Cessation
-
2013
- 2013-04-02 IL IL225507A patent/IL225507B/en active IP Right Grant
-
2015
- 2015-09-02 US US14/843,480 patent/US20160220554A1/en not_active Abandoned
-
2016
- 2016-07-08 AU AU2016204747A patent/AU2016204747A1/en not_active Abandoned
-
2017
- 2017-02-28 JP JP2017036322A patent/JP2017149714A/ja active Pending
-
2020
- 2020-06-18 US US16/905,307 patent/US11612597B2/en active Active
-
2023
- 2023-02-21 US US18/112,214 patent/US11969419B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2621481T4 (da) | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser | |
DK3178849T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
DK2435432T6 (da) | Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme | |
DK2507211T3 (da) | Apoptosefremkaldende midler til behandling af cancer og immun- og autoimmun-sygdomme | |
DK2511264T3 (da) | Apoptose-inducerende midler til behandling af cancer og immunsygdomme og autoimmune sygdomme | |
DK2785744T3 (da) | Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf | |
DK3489261T3 (da) | Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase | |
DK3444342T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme | |
DK2632954T4 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
DK2558105T3 (da) | Bardoxolonmethyl til behandling af fedme | |
DK2790738T3 (da) | Biomarkører for kollateral geninaktivering og mål for cancerterapi | |
DK2532366T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
DK3400944T3 (da) | Ibat-inhibitorer til behandling af leversygdomme | |
DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
DK2473510T3 (da) | Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer | |
BR112013012078A2 (pt) | inibidores de nampt e rock | |
DK3150240T3 (da) | Systemer og fremgangsmåder til fremføring af terapeutiske midler | |
EA201490944A1 (ru) | Двойной ингибитор met и vegf для лечения рака | |
DK2544679T3 (da) | Pde10-inhibitorer og relaterede sammensætninger og fremgangsmåder | |
DK2398902T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer | |
DK3246042T3 (da) | Lægemiddelresistent immunterapi til behandling af cancer | |
DK3443957T3 (da) | Forbindelser og sammensætninger til behandling af cancer | |
ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
DK3650125T3 (da) | Væskeforstøver og fremgangsmåder | |
EA202190820A1 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты |